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Abstract
Introduction: Uptake of early infant HIV diagnosis (EID) varies widely across sub-Saharan African settings. We evaluated the
potential clinical impact and cost-effectiveness of universal maternal HIV screening at infant immunization visits, with referral
to EID and maternal antiretroviral therapy (ART) initiation.
Methods: Using the CEPAC-Pediatric model, we compared two strategies for infants born in 2017 in Côte d’Ivoire (CI), South
Africa (SA), and Zimbabwe: (1) existing EID programmes offering six-week nucleic acid testing (NAT) for infants with known
HIV exposure (EID), and (2) EID plus universal maternal HIV screening at six-week infant immunization visits, leading to refer-
ral for infant NAT and maternal ART initiation (screen-and-test). Model inputs included published Ivoirian/South African/Zimbab-
wean data: maternal HIV prevalence (4.8/30.8/16.1%), current uptake of EID (40/95/65%) and six-week immunization
attendance (99/74/94%). Referral rates for infant NAT and maternal ART initiation after screen-and-test were 80%. Costs
included NAT ($24/infant), maternal screening ($10/mother–infant pair), ART ($5 to 31/month) and HIV care ($15 to 190/
month). Model outcomes included mother-to-child transmission of HIV (MTCT) among HIV-exposed infants, and life expec-
tancy (LE) and mean lifetime per-person costs for children with HIV (CWH) and all children born in 2017. We calculated incre-
mental cost-effectiveness ratios (ICERs) using discounted (3%/year) lifetime costs and LE for all children. We considered two
cost-effectiveness thresholds in each country: (1) the per-capita GDP ($1720/6380/2150) per year-of-life saved (YLS), and (2)
the CEPAC-generated ICER of offering 2 versus 1 lifetime ART regimens (e.g. offering second-line ART; $520/500/580/YLS).
Results: With EID, projected six-week MTCT was 9.3% (CI), 4.2% (SA) and 5.2% (Zimbabwe). Screen-and-test decreased total
MTCT by 0.2% to 0.5%, improved LE by 2.0 to 3.5 years for CWH and 0.03 to 0.07 years for all children, and increased dis-
counted costs by $17 to 22/child (all children). The ICER of screen-and-test compared to EID was $1340/YLS (CI), $650/YLS
(SA) and $670/YLS (Zimbabwe), below the per-capita GDP but above the ICER of 2 versus 1 lifetime ART regimens in all coun-
tries.
Conclusions: Universal maternal HIV screening at immunization visits with referral to EID and maternal ART initiation may
reduce MTCT, improve paediatric LE, and be of comparable value to current HIV-related interventions in high maternal HIV
prevalence settings like SA and Zimbabwe.
Keywords: Early infant diagnosis; HIV; paediatric HIV testing; HIV-exposed infants; immunization; prevention of mother-to-child
HIV transmission
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In 2019, more than 1.2 million infants were born to women
with HIV worldwide and 150,000 acquired HIV [1]. Prompt
diagnosis and treatment are critical to the survival of infants
with HIV; without treatment, >50% will die before two years
of age [2]. Diagnosis of infant HIV requires a nucleic acid test
(NAT) because passively transferred maternal anti-HIV anti-
bodies cannot be differentiated from those endogenously pro-
duced in children with HIV (CWH) up to 18 months of age
[3]. NAT-based early infant HIV diagnosis (EID) is recom-
mended for all infants with known HIV exposure (i.e. born to
HIV status-aware mothers), with prompt initiation of antiretro-
viral therapy (ART) for CWH [3,4]. However, only 60% of
HIV-exposed infants were tested globally by two months of
age in 2019, with 68% in Eastern and Southern Africa but
only 33% in Western and Central Africa [1]. Low EID uptake
is due partly to lack of knowledge of maternal HIV status
(thus infant exposure), and loss to follow-up before NAT is
undertaken among infants known to be HIV-exposed.
To improve access to EID, pilot projects have demonstrated
the feasibility and acceptability of maternal HIV screening at
infant six-week expanded programme on immunization (EPI)
visits, where attendance is often >90% [5-9]. This practice can
identify HIV-exposed infants not engaged in existing EID pro-
grammes and mothers who need ART, simultaneously improv-
ing maternal health and reducing the risk of HIV transmission
to breastfed, HIV-uninfected children. However, of concerns
are the costs of these programmes, which require screening
large numbers of women and, in some settings, may have low
yield in identifying HIV-exposed infants not engaged in EID
services. We used a validated computer simulation model to
examine the clinical impact and cost-effectiveness of adding
routine maternal HIV screening at immunization visits, with
referral to infant HIV testing at existing EID programmes in
Côte d’Ivoire (CI), South Africa (SA) and Zimbabwe.
2 | METHODS
2.1 | Model overview
We used the Cost-Effectiveness of Preventing AIDS Complica-
tions (CEPAC)-Pediatric model, a validated Monte Carlo simu-
lation model of paediatric HIV acquisition, disease progression,
diagnosis and treatment [10-14]. Children were simulated
from birth until death. In the model, children who are HIV-ex-
posed have a risk of intrauterine or intrapartum HIV acquisi-
tion dependent on maternal ART use during pregnancy
(reflecting prevention of mother-to-child transmission
[PMTCT] coverage) and CD4 count (reflecting disease stage).
Children who are HIV-exposed but uninfected face a monthly
risk of postnatal HIV acquisition based on maternal ART use,
infant antiretroviral prophylaxis and maternal disease stage
(including acute infection during breastfeeding) until cessation
of breastfeeding, and no risk thereafter. All simulated children
face monthly risks of non-HIV-related mortality. CWH face
additional risks of opportunistic infections (OIs), and OI- and
HIV-related mortality based on their CD4% (age <5 years) or
CD4 count (age ≥5 years), retention of care and ART use.
Details of HIV disease progression; ART regimens, monitoring
and outcomes; and loss to follow-up and return to care, are
provided in the Appendix and at https://mpec.massgeneral.
org/cepac-model/.
2.2 | Population and strategies
We simulated all infants born in CI, SA and Zimbabwe in
2017 (the most recent year for which complete data were
available), including infants born to women with and without
HIV. These countries represent variation in key characteristics
of the HIV epidemic, including maternal HIV prevalence (low/
high/medium), EID uptake (low/moderate/high), maternal ART
coverage (low/high/high) and income level (low/low/middle).
Country guidelines recommend EID at six weeks of age for
most infants in CI and Zimbabwe, and at birth and 10 weeks
of age in SA; both are consistent with World Health Organiza-
tion recommendations. We modelled six-week EID for all
countries to permit us to isolate the most influential parame-
ters (EPI uptake, screening costs and care costs).
We compared two strategies in each setting: (1) six-week
NAT for infants with known HIV exposure (EID), and (2) EID
plus universal maternal rapid diagnostic testing (RDT) at six-
week infant immunization visits, with positive result leading to
referral for infant NAT and maternal ART initiation (screen-
and-test). In screen-and-test, HIV status-aware mothers who did
not attend an EID visit at six weeks with their infant, but pre-
sented to an EPI visit, could be referred back to an EID clinic
for NAT. In both strategies, we simulated a confirmatory NAT
algorithm before ART initiation. Children who develop an OI
and are not in care experience a probability of presenting to
care, undergoing HIV testing and linking to care. Women with
HIV were not directly simulated in either strategy; rather,
maternal characteristics were reflected in changes in infant
HIV acquisition risk over time.
2.3 | Model input parameters
We derived clinical data to inform cohort characteristics,
MTCT risks, assay characteristics and treatment outcomes
from published trials and cohort studies in sub-Saharan Africa
(Table 1, Sections I-III) [15-35]. We used Ivoirian, South Afri-
can and Zimbabwean programmatic data for three separate
country-specific base-case analyses (Table 1, Section IV), and
varied these parameters from sensitivity analyses. We used
national estimates of maternal HIV prevalence during preg-
nancy (4.8%, 30.8%, 16.1%) and postpartum maternal HIV
incidence (0.4/100 person-years (PY), 2.9/100PY, 1.5/100 PY)
[36-39]. Maternal knowledge of HIV status during pregnancy
(86%, 89%, 84%) reflected the product of antenatal care
(ANC) attendance (91%, 94%, 93%) and HIV testing coverage
during ANC or at delivery (95%, 95%, 90%) [36-38,40].
Maternal ART coverage during both pregnancy and breast-
feeding (70%, 95%, 95%) and uptake of existing EID pro-
grammes (40%, 95%, 65%) were from UNAIDS data [36]. In
screen-and-test, the probability of maternal screening was the
product of six-week immunization coverage (99%, 74%, 94%),
which was derived from UNICEF country-specific data, and a
90% probability of offer and acceptance of testing [5-9,41]. At
EPI visits, newly diagnosed mothers and HIV status-aware
mothers who missed an EID visit at six weeks had a modelled
80% probability of successful referral to existing EID pro-
grammes [42]. We assumed that the probability of maternal
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Table 1. Selected base-case input parameters for the CEPAC-Paediatric model analysis of EID and screen-and-test
Variable Base-case value References
I. Clinical input parameters
Male infants, % 48 [48]
Mothers with CD4 ≤ 350/µL before ART, % 49 [83]
Infant CD4% at infection, mean (SD) 45 (10) [11]
IU/IP MTCT (one-time risk in pregnancy/delivery, %) Maternal CD4 ≤ 350/µL Maternal CD4 > 350/µL
On ART 0.93 0.93 [15–18]
Not on ART 27 17 [19–24]
PP MTCT (monthly risk during breastfeeding, %)
On ART 0.19 0.19 [25–29]
Not on ART
Exclusive breastfeeding 0.76 0.24 [19,30–32]
Mixed or complementary breastfeeding 1.28 0.40 [19,30–32]
II. Assay characteristics
NAT sensitivity, specificity for infant HIV, %
IU infection: all ages, % 100, 99.6 [79,84–86]
IP/PP infection: month in which infection occurs, % 0, 99.6 [79,84–86]
IP/PP infection: subsequent months, % 100, 99.6 [79,84–86]
RDT sensitivity, specificity for maternal HIV, % 99.9, 100 [87,88]
III. Art Outcomes (first-line ART) (second-line ART)
ART efficacy: HIV RNA < 400c/mL at 24 weeks on ART, %
Ages <5 years 91 75 [33,34]
Ages ≥5 years 75 75 [35]
CD4 count increase, mean CD4%/month, range by month 0.7 to 2.2 0.4 to 1.9 [33,34]
Monthly loss to follow-up after ART initiation, % 0.2 [89,90]
IV. Country-specific clinical parameters Côte d’Ivoire South Africa Zimbabwe
Antenatal
Maternal HIV prevalence, % 4.8 30.8 16.1 [36,91]
Maternal knowledge of HIV status, %a 86 89 84 [36–38,40]
Postnatal
Maternal HIV incidence (/100PY) 0.4 2.9 1.5 [39]
Mean breastfeeding duration, months 12 12 18 [37,40,92]
Proportion of infants breastfed from birth, % 80 80 80 [93,94]
Breastfeeding for first six months: exclusive, mixed, % 25, 55 55, 25 55, 25 [94,95] Assumption
Maternal ART coverage in pregnancy/breastfeeding (PMTCT), % 70 95 95 [36]
Routine 6-week EID for infants with known HIV exposure:
Uptake of existing EID programmes, % 40 95 65 [36]
Linkage to care/ART after positive EID test, % 71 71 71 [43,44]
Maternal HIV testing at infant immunization visits
Immunization coverage (six to ten weeks), % 99 74 94 [41]
Offer and acceptance of maternal RDT, % 90 90 90 [5,7–9]
Linkage to care/ART for newly diagnosed mothers, % 80 80 80 [42]
Linkage to NAT for HIV-exposed infants, % 80 80 80 Assumption
Linkage to care/ART for diagnosed infants referred from EPI, % 71 71 71 [43,44]
V. Costs (2018 USD) Côte d’Ivoire South Africa Zimbabwe
Routine HIV care, per month (range by CD4%/count)c 20 to 190 15 to 140 30 to 35 [54–58]
Acute OI care (range by type of OI) 60 to 480 210 to 1,490 –b [54–58]
Paediatric ART, per month (range by ART regimen) 5 to 31 5 to 31 5 to 31 [59,60]
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linkage to HIV care and ART after the EID visit was equal to
country-specific maternal ART coverage. Once diagnosed
through any mechanism, including detection after OI, infants
had a 71% probability of linking to HIV care and ART in all
countries [43,44].
We derived country- and sex- specific mortality rates for
HIV-unexposed children from UNAIDS HIV-deleted life
tables, and mortality rates for HIV-exposed/uninfected infants
from pooled UNAIDS analyses [45,46]. Therefore, life expec-
tancy (LE) projections are not expected to be directly compa-
rable across country settings. Risks of disease progression
without ART were calibrated to survival data for African chil-
dren and adults [11,47-52]. Survival and OI risks for children
and adults on ART were calibrated to clinical trial data
[11,33-35,49,53].
We modelled costs of HIV testing and clinical care in 2018
USD (Table 1, Section V). Costs specific to each country
included routine HIV care (e.g., laboratory monitoring, person-
nel, facilities) and acute OI care [54–58]. ART costs ranged by
age and weight ($5 to 31/month) and were derived from Clin-
ton Health Access Initiative price lists and World Health
Organization weight-based dosing [59,60]. Assay costs were
modelled as “fully loaded,” including personnel time and train-
ing, and were derived from Global Fund and published HIV
testing reports: NAT ($24/assay), maternal HIV screening
($10/mother–infant pair: $3 for RDT plus personnel and train-
ing costs; Appendix p3) and ART monitoring (CD4: $5 to 12/
assay; HIV RNA: $17 to 32/assay) [56,61-64]. In screen-and-
test, per-person lifetime costs included the cost of maternal
ART during breastfeeding for mothers diagnosed and linked
to care through screening.
2.4 | Model outcomes
Primary model outcomes were MTCT proportion at six weeks
and after weaning, incremental yield of the screening pro-
gramme (the additional number of infants identified with HIV
divided by the number of women reached by the screen-and-
test programme), proportion of all CWH identified and linked
to care, 1- and 2-year survival, LE (years) and average per-
person lifetime costs from a healthcare system perspective
(2018 USD). We projected outcomes for both CWH and the
complete birth cohort (including CWH, uninfected children
with HIV exposure and HIV-unexposed children), but not for
mothers.
Using discounted (3%/year) birth cohort outcomes, we cal-
culated incremental cost-effectiveness ratios (ICERs) in USD
per year-of-life saved ($/YLS). In the absence of consensus
about country-specific cost-effectiveness thresholds, we com-
pared ICERs to (1) the 2018 per-capita GDP in each country
(CI: $1720/YLS, SA: $6380/YLS, Zimbabwe: $2150/YLS), and
(2) the CEPAC-generated ICER of a paediatric HIV pro-
gramme offering 2 versus 1 lifetime ART regimens (e.g., offer-
ing second-line ART; CI: $520/YLS, SA: $500/YLS, Zimbabwe:
$580/YLS) [65-68]. This ICER can be used to estimate the
health benefits that would be foregone by diverting resources
from an existing programme to a novel intervention, as a rea-
sonable proxy for the value of alternative claims upon limited
resources for HIV services. We varied cost-effectiveness
thresholds in sensitivity analyses.
2.5 | Scenario analysis
We examined the impact of a birth and 10-week EID schedule
in SA. Modelled EID coverage was 67% at birth and 80% at
10 weeks [69]. HIV status-aware mothers who presented to
an EPI visit at six weeks, but whose infant did not receive a
test at birth, could be referred back to an EID clinic in the
next month.
2.6 | Univariate and multivariate sensitivity
analyses
We followed international guidance on uncertainty analysis
and reported extensive univariate and multivariate uncertainty
analyses, using literature-based estimates of the uncertainty
around key parameters [70]. For each country, we varied key
epidemic-specific parameters, uptake at each care “cascade”
step for EID and screen-and-test, and costs of diagnostics and
HIV care. We first varied these parameters through their pub-
lished ranges, where available, to identify the impact of data
uncertainty on results, including: maternal HIV prevalence,
knowledge of HIV status, HIV incidence and ART coverage
during pregnancy and breastfeeding; uptake of existing EID
programmes; immunization coverage; and cost of infant NAT.
We next evaluated wider ranges for remaining parameters
where data-informed ranges were unavailable (e.g. linkage to
EID after screening and screening costs) in order to identify
the threshold values at which screen-and-test would reach each
cost-effectiveness threshold. Table S1 shows the ranges
Table 1. (Continued)
Variable Base-case value References
NAT, per assay 24 24 24 [62]
Maternal screening programme, per mother–infant paird 10 10 10 [61]
ANC, antenatal care; ART, antiretroviral therapy; EID, early infant diagnosis; EPI, expanded programme on immunization; IP, intrapartum; IU,
intrauterine; MTCT, mother-to-child transmission; NAT, nucleic acid test; OI, opportunistic infection; PP, postpartum; PY, person-years; RDT, rapid
diagnostic test; SD, standard deviation.
a
Maternal knowledge of HIV status was calculated from the product of ANC coverage and frequency of HIV testing in ANC in each country.;
b
Based on available data, for CI and SA we modelled costs of care for individual OIs; in Zimbabwe, OI care was included in overall monthly care
costs.;
c
CD4% is used for ages <5 years, CD4 count used for ages ≥5.;
d
Overall cost reflects both the cost of a maternal rapid diagnostic test and
programme implementation costs.
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through which parameters were varied. In multivariate sensi-
tivity analyses, we varied the most influential individual param-
eters simultaneously.
3 | RESULTS
3.1 | Base-case results: clinical outcomes
In CI (Table 2, top rows), 5.2% of infants was projected to
have HIV exposure during pregnancy/breastfeeding. Among
HIV-exposed infants, projected six-week MTCT was 9.3% in
both strategies; total MTCT at weaning was 11.7% with EID
and 11.5% with screen-and-test. Most infections occurred
among infants born to mothers who were unaware of their
status; in this group, six-week MTCT was 21.9% in both
strategies and total MTCT at weaning was 25.2% with EID
and 23.8% with screen-and-test. Table 2 also shows corre-
sponding results for SA and Zimbabwe. For all infants born in
2017, screen-and-test was projected to save 13 550 to 29 680
life-years in CI, SA and Zimbabwe (Table S2). The incremental
yield for the screen-and-test programme was 0.20% in CI,
0.53% in SA and 0.42% in Zimbabwe, suggesting that a pro-
gramme would need to screen 500 mothers in CI, 190 in SA
and 240 in Zimbabwe to identify one additional infant with
HIV, compared to EID alone.
Among CWH, EID led to lower projected two-year survival
(CI: 58.5%, SA: 58.7%, Zimbabwe: 60.3%) compared to screen-
and-test (CI: 67.3%, SA: 63.7%, Zimbabwe: 67.1%; Figure S1).
Screen-and-test increased the proportion of infants with
intrauterine or intrapartum HIV acquisition detected before
development of an OI or death (Figure 1, Table S3). In CI, the
LE for CWH was 20.42 years with EID and 23.90 years with
screen-and-test (Table 2). Gains in LE followed a similar trend
in SA (EID: 19.74 years, screen-and-test: 21.69 years) and Zim-
babwe (EID: 19.77 years, screen-and-test: 22.49 years).
The impact of EID and screen-and-test on the survival of the
entire birth cohort was smaller, because HIV-unexposed
infants, who made up the majority of the population, did not
benefit from either strategy. For example, two-year survival in
CI was 94.21% with EID and 94.26% with screen-and-test, and
LE was 65.72 and 65.75 years respectively (Table 2).
3.2 | Base-case results: lifetime costs and cost-
effectiveness
With EID, mean discounted per-person lifetime HIV-related
costs for the entire birth cohort were $40 in CI, $160 in SA
and $80 in Zimbabwe (Table 2). Screen-and-test increased pro-
jected costs by $20/child in all settings (to $60/infant in CI,
$180/infant in SA and $100/infant in Zimbabwe), reflecting
not only the additional cost of screening and EID programmes,
but also greater costs for clinical care and ART as more
infants were diagnosed and linked to HIV care and treatment
(Figure S2).
Lifetime cost-effectiveness results showed that the ICER of
screen-and-test versus EID was $1340/YLS in CI (78% of the
per-capita GDP; 258% of the ICER of 2 versus 1 lifetime ART
regimens), $650/YLS in SA (10% of the per-capita GDP; 130%
of the ICER of 2 versus 1 lifetime ART regimens) and $670/
YLS in Zimbabwe (31% of the per-capita GDP; 116% of the
ICER of 2 versus 1 lifetime ART regimens).
3.3 | Scenario analysis
Compared to the base case, a birth and 10-week EID sched-
ule in SA resulted in slightly greater clinical benefit for CWH
in both the EID and screen-and-test strategies (19.77 and
21.95 years respectively) due to more opportunities for EID
(Table 2), but similar results for the entire birth cohort within
rounding, and a similar ICER of screen-and-test versus EID.
3.4 | Univariate sensitivity analyses
Among parameters with available data-informed ranges (Fig-
ure 2, blue bars), maternal HIV prevalence exerted the great-
est influence on the cost-effectiveness of screen-and-test
versus EID in CI; with the lowest published prevalence (2%),
the ICER exceeded the per-capita GDP (Figure 2A). With
higher prevalence or lower knowledge of maternal HIV status,
as might be seen in sub-national Ivoirian settings, the ICER
was lower than in the base case, although never reached the
ICER of 2 versus 1 lifetime ART regimens. In SA and Zim-
babwe, maternal knowledge of HIV status had the greatest
impact on the ICER of screen-and-test versus EID and the low-
est reported value of maternal knowledge of HIV status led
the ICER to fall below the ICER of 2 versus 1 lifetime ART
regimens (Figures 2B,C).
Among parameters without available data-informed ranges
(Figure 2, grey bars), the ICER of screen-and-test versus EID
was most sensitive to assumptions about screening pro-
gramme costs, infant linkage to NAT after maternal screening,
breastfeeding duration and routine HIV care costs in all three
countries. In CI, even when the most favourable values for
screen-and-test were assumed, the ICER never fell below
$520/YLS (the ICER of 2 versus 1 lifetime ART regimens),
although it was often below the per-capita GDP (Figure 2A). In
SA and Zimbabwe, the ICER was often near or below the
ICER of 2 versus 1 lifetime ART regimens (falling below this
threshold when infant linkage to NAT after maternal screening
was low or breastfeeding duration was high), and never
exceeded the per-capita GDP (Figures 2B,C). Wide variations
in all other key model input parameters did not substantially
affect the ICER of screen-and-test versus EID.
3.5 | Multivariate sensitivity analyses
Figure 3 shows the joint impact of variation in key pairs of
parameters: maternal HIV prevalence and awareness of HIV
status (top three panels), and infant linkage to NAT after
maternal screening and the cost of the screening programme
(bottom three panels). In CI, plausible variations in maternal
HIV prevalence or knowledge of HIV status led screen-and-test
to meet the per-capita GDP cost-effectiveness threshold (light
green shading) but not the ICER of 2 versus 1 lifetime ART
regimens (dark green shading) (top left panel) [36,71]. In CI,
the screen-and-test programme (exclusive of subsequent NAT
and ART) would need to achieve high (>50%) infant linkage to
NAT and cost <$15/mother–infant pair to meet even the per-
capita GDP cost-effectiveness threshold (bottom left panel).
The cost-effectiveness of screen-and-test versus EID in SA
and Zimbabwe followed similar directional trends, although
with more scenarios in which screen-and-test was cost-effec-
tive. Screen-and-test met one or both cost-effectiveness
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thresholds except when maternal HIV prevalence was lower
than the base case (SA: <10%, Zimbabwe: <15%) and mater-
nal knowledge of HIV status was simultaneously high (SA:
>90%. Zimbabwe: >70%) (top middle and right panels). Screen-
and-test met one or both cost-effectiveness thresholds in SA
over all ranges explored for infant linkage to NAT and screen-
ing costs (bottom middle panel), and in Zimbabwe when infant
linkage to NAT was >30% and the screening programme cost
was <$35 (bottom right panel). When screening costs were <
$10 in SA and <$5 in Zimbabwe, screen-and-test would still be
cost-effective even if infants were not diagnosed or linked to
care, and the only benefits were a reduction in postpartum
MTCT resulting from maternal diagnosis and ART initiation. In
CI, in contrast, where maternal HIV prevalence is lower,
Table 2. Base-case model projections of EID and screen-and-test in Côte d’Ivoire, South Africa and Zimbabwe





















% % % years years years USD 2018 USD 2018 $/YLS
Côte d’Ivoire
EID 5.2 9.3 11.7 20.42 65.72 26.86 80 40
Screen-and-test 5.2 9.3 11.5 23.90 65.75 26.87 100 60 1340
South Africa
EID 32.8 4.2 6.2 19.74 63.26 26.51 280 160
Screen-and-test 32.8 4.2 6.0 21.69 63.33 26.54 310 180 650
Zimbabwe
EID 17.3 5.2 8.5 19.77 64.58 26.42 140 80
Screen-and-test 17.3 5.2 8.0 22.49 64.65 26.45 170 100 670
Scenario Analysis: EID at birth and 10 weeks in South Africa
EID 32.8 4.2 6.2 19.77 63.26 26.51 280 160
Screen-and-test 32.8 4.2 6.0 21.95 63.33 26.54 310 180 620
CWH, children with HIV; ICER, incremental cost-effectiveness ratio; MTCT, mother-to-child transmission; USD, United States dollar; YLS, year-of-
life saved.
a
MTCT outcomes are reported among all HIV-exposed infants.;
b
Life expectancies are rounded to two decimals, costs are rounded to the nearest
$10. ICERs were calculated from discounted (3%/year) life expectancies and costs prior to rounding.
Figure 1. Mechanisms of HIV detection among children ever infected with HIV at 1 year from birth in the screen-and-test strategy in Côte
d’Ivoire.Bar graph representing mechanisms of HIV detection among simulated infants with the proposed screen-and-test strategy.
The left bar represents the proportions alive and dead at 1 year from birth of all infants who had acquired HIV by that time; results are reported
separately for infants who acquired HIV during the IU/IP (dark green) vs. PP (light green) periods. The bottom right (IU/IP) and top right (PP) bars
provide further details about the proportion of infants alive at 12 months of age who are undetected or were detected by an OI, existing EID
programmes, or the screen-and-test programme. Similar results were observed in South Africa and Zimbabwe (see Appendix Table S3). Abbrevia-
tions: EID, early infant diagnosis; IP, intrapartum; IU, intrauterine; OI, opportunistic infection; PP, postpartum.




500 1,500 2,500 3,500 4,500 5,500
Proportion of infants breastfed from birth (100-60%; 80%)
Maternal linkage to care after screen-and-test (100-30%; 80%)
Uptake of existing EID programs (27-62%; 40%)
Pediatric ART costs (0.5-2x; range by age and ART line)
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Figure 2. Univariate sensitivity analysis examining the impact of key input parameters on the cost-effectiveness of screen-and-test compared
to EID in (A) Côte d’Ivoire, (B) South Africa and (C) Zimbabwe.
Univariate sensitivity analyses describing the impact of key input parameters on cost-effectiveness results. The horizontal axis shows the incre-
mental cost-effectiveness ratio of screen-and-test compared to EID. The range through which each parameter is varied is shown in parentheses
(value leading to the lowest shown ICER first, followed by value leading to the greatest shown ICER, with base-case value after the semicolon).
The length of each bar reflects the degree to which cost-effectiveness is sensitive to variations in each parameter, with longest bars (greatest
impact) at the top. Dark blue bars represent parameters for which published data ranges were available (data-informed parameters, evaluated to
understand the impact of parameter uncertainty on model outcomes); grey bars represent parameters for which no detailed data ranges were
available (and thus wide ranges were evaluated to identify thresholds at which policy conclusions would change). The cost-effectiveness criteria
used are as follows: (1) the ICER of 2 versus 1 lifetime ART regimens (Côte d’Ivoire: $520/YLS; South Africa: $500/YLS; Zimbabwe: $580/YLS),
and 2) the per-capita GDP/YLS (Côte d’Ivoire: $1720/YLS; South Africa: $6380/YLS; Zimbabwe: $2150/YLS). Maternal HIV prevalence and inci-
dence were varied together, holding the ratio of incidence to prevalence constant (0.008), to capture plausible variation in severity of the HIV epi-
demic. Several parameters did not influence the ICER of screen-and-test versus EID and thus are not shown here: In Côte d’Ivoire, the ICER of
screen-and-test compared to EID was not sensitive to 3 parameters varied through data-informed ranges (maternal HIV incidence [when varied
alone], immunization coverage and the cost of infant NAT) and 1 parameter varied through wide ranges (acute OI care costs). In South Africa, the
ICER of screen-and-test compared to EID was not sensitive to five parameters varied through data-informed ranges (maternal HIV prevalence,
maternal HIV incidence [when varied alone], immunization coverage, maternal ART coverage during pregnancy/breastfeeding and the cost of infant
NAT) and 2 parameters varied through wide ranges (infant linkage to care after EID and acute OI care costs). In Zimbabwe, the ICER of screen-
and-test compared to EID was not sensitive to 3 parameters varied through data-informed ranges (maternal HIV incidence [when varied alone],
maternal ART coverage during pregnancy/breastfeeding and the cost of infant NAT) and 1 parameter varied through wide ranges (infant linkage
to care after detection by OI). All other input parameters shown in Table 1 were not influential on the ICER of screen-and-test versus EID in any
country setting. Abbreviations: ART, antiretroviral therapy; EID, early infant diagnosis; ICER, incremental cost-effectiveness ratio; NAT, nucleic test;
YLS, year-of-life saved
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screen-and-test would need to afford greater clinical benefit
than just a reduction in postpartum MTCT to be cost-effec-
tive.
4 | DISCUSSION
In this model-based analysis, we evaluated the clinical impact
and cost-effectiveness of a maternal HIV screening pro-
gramme at immunization visits in Côte d’Ivoire, South Africa
and Zimbabwe, with subsequent referral to EID and maternal
ART initiation. We observed three key findings.
First, screen-and-test substantially improved LE for CWH
and reduced postpartum MTCT in all three countries. For
CWH, projected two-year survival improved by an absolute
amount of 5.0% to 8.8% and LE increased by 2.0 to 3.5 years,
compared to EID. Although these gains are substantial com-
pared to other medical therapies, they are accrued only to a
small proportion of children in the birth cohort. Nonetheless,
they were large enough to lead to gains in LE at the entire
population-level (0.36 to 0.84 life-months) similar to projected
LE gains from many other currently funded interventions [72].
Among children with HIV exposure, 18-month MTCT
decreased by 0.2% to 0.5%. Infants born to HIV status-
unaware mothers, who experience the greatest risk of acquir-
ing HIV, benefited greatly from a screen-and-test programme
that could facilitate infant and maternal diagnosis and ART ini-
tiation. Infants born to HIV status-aware mothers also bene-
fited, because EID uptake is not perfect (40% to 95%), and
screen-and-test provided an additional opportunity for these
infants to be re-referred to EID at well-child immunization vis-
its.
Second, screen-and-test was more costly than EID. Greater
per-person lifetime costs with screen-and-test were due pri-
marily due to caring for CWH over their lifetimes (Figure S2).
Although costlier, screen-and-test was below the per-capita
GDP threshold in all three countries. Screen-and-test was more
economically favourable in SA and Zimbabwe than in CI partly
because fewer mothers would need to be screened to identify
one additional infant with HIV compared to EID alone (190 in
SA, 240 in Zimbabwe, and 500 in CI). Country differences
were also due to key epidemic factors. In SA and Zimbabwe,
where maternal HIV prevalence is high, cost-effectiveness was
due to more timely identification and treatment of infants liv-
ing with HIV and a reduction in postpartum MTCT. Although
CI has a lower maternal HIV prevalence, simultaneously low
rates of maternal HIV testing and PMTCT uptake led to high
numbers of infants missed by routine EID and contributed to
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Figure 3. Multivariate analyses examining the impact of simultaneously varying maternal HIV prevalence and maternal knowledge of HIV
status (top three panels), and infant linkage to NAT after maternal screening and the cost of the screening programme (bottom three panels)
in Côte d’Ivoire, South Africa and Zimbabwe.
Multivariate sensitivity analyses describing the joint impacts of maternal HIV prevalence and maternal awareness of HIV status (top three panels),
and infant linkage to NAT after screen-and-test and the cost of the screening programme (bottom three panels) on cost-effectiveness results. The
cost-effectiveness criteria used are as follows: (1) the ICER of 2 versus 1 lifetime ART regimens (Côte d’Ivoire: $520/YLS; South Africa: $500/
YLS; Zimbabwe: $580/YLS), and 2) the per-capita GDP/YLS (Côte d’Ivoire: $1720/YLS; South Africa: $6380/YLS; Zimbabwe: $2150/YLS). Red por-
tions of the figure represent conditions where screen-and-test is not cost-effective by either cost-effectiveness criteria (the ICER of screen-and-test
compared to EID is greater than the ICER of 2 versus 1 lifetime ART regimens and greater than the per-capita GDP/YLS). Light green shading rep-
resents an ICER greater than the ICER of 2 versus 1 lifetime ART regimens but less than the per-capita GDP/YLS. Dark green shading represents
an ICER less than the ICER of 2 versus 1 lifetime ART regimens and less than the per-capita GDP/YLS. Abbreviations: ART, antiretroviral therapy;
ICER, incremental cost-effectiveness ratio; NAT, nucleic acid test.
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the value of the screen-and-test strategy. In addition, in CI,
because uptake of existing EID programmes is also low, the
cost-effectiveness was also due in part to a second opportu-
nity for infant testing among HIV status-aware mothers. The
determination of whether health interventions are “cost-effec-
tive” depends heavily upon a country’s willingness to pay for
health. The widely cited per-capita GDP-based cost-effective-
ness threshold may be too high in resource-limited settings:
investing in health interventions with ICERs near the per-cap-
ita GDP may forego health benefits by diverting resources
from better-value interventions [68,73-75]. Although the ICER
of screen-and-test versus EID was lower than the per-capita
GDP in all three countries, it exceeded the ICER of the bench-
mark intervention of offering 2 versus 1 lifetime ART regi-
mens to CWH. However, the ICER of screen-and-test versus
EID compares favourably to other funded HIV-related inter-
ventions in SA and Zimbabwe, such as existing EID pro-
grammes compared to no EID (CEPAC-generated ICERs of
$1250/YLS and $1050/YLS respectively) [13,14]. In low
maternal HIV prevalence settings such as CI, screen-and-test
would be a less valuable strategy than alternative investments
such as paediatric care offering two ART regimens, but sensi-
tivity analyses suggested potential cost-effectiveness in subna-
tional Ivoirian settings where maternal knowledge of HIV
status is low or maternal HIV prevalence or breastfeeding
duration is high.
Third, several key factors influenced the cost-effectiveness
of the screen-and-test versus EID. In all three countries,
cost-effectiveness depended on screening programme cost,
infant linkage to NAT after referral from the screening pro-
gramme, and maternal knowledge of HIV status during
pregnancy. These findings have important implications for
the potential implementation of screen-and-test programmes.
There are minimal data to inform the proportion of HIV-ex-
posed infants that would link to NAT and HIV care if
screen-and-test were implemented nationally. One recent
study of intra-facility linkage to HIV chronic care for moth-
ers identified as HIV-infected during ANC in Uganda found
that only 37% of women transferred to a new clinic setting,
and only 30% of all HIV-exposed infants linked to EID pro-
grammes [76]. Even if linkage to infant NAT were this low,
screen-and-test would still be cost-effective in SA and Zim-
babwe (Figure 3).
Although screen-and-test would improve clinical outcomes
and likely be cost-effective in SA and Zimbabwe, and perhaps
in specific settings within CI, key questions about the imple-
mentation and relative value of alternative paediatric HIV
case-finding approaches remain unanswered. Screen-and-test
would require screening large numbers of women in order to
identify one CWH. Additional strategies to identify HIV-ex-
posed infants (e.g. maternal testing during pregnancy, labour
and/or breastfeeding) and diagnose CWH (e.g. routine testing
at nutrition, inpatient and tuberculosis clinics) may have differ-
ent testing yields, clinical benefit and cost-effectiveness. There
is also limited knowledge about the feasibility of adding HIV
testing into already busy EPI clinics, or about the amount of
additional healthcare personnel time and training required.
Additionally, a pilot effort to introduce HIV testing in Tanza-
nian EPI clinics reportedly reduced vaccine acceptance, per-
haps due to concerns about HIV testing [9], although other
pilot studies showed no such reduction [5,6]. Lower
vaccination rates and increased rates of vaccine-preventable
illness among children might outweigh the benefits of addi-
tional infant HIV diagnosis and prevention of postnatal HIV
acquisition.
There are several limitations in this analysis. First, treat-
ment availability, clinical care and healthcare costs are likely
to change over infants’ lifetimes, rendering long-term model-
based projections for children uncertain. We addressed this
uncertainty by calibrating our model to currently available
survival, MTCT risk and OI data, and varying epidemic-speci-
fic and treatment parameters that are likely to change over
time. Except where noted, model-based policy conclusions
were robust to plausible changes in these parameters. Sec-
ond, we did not evaluate clinical outcomes, costs or potential
reduced MTCT in subsequent pregnancies among mothers.
The long-term benefits and costs among newly diagnosed
mothers would be expected to be of comparable or greater
value to HIV testing programmes in adults, and including
maternal outcomes would likely improve the cost-effective-
ness of screen-and-test [61,77]; integrated maternal and infant
HIV services has been shown to be cost-effective for
mother–infant pairs in SA [78]. Third, we modelled costs
from a healthcare system perspective, which does not
account for societal costs incurred (e.g. patient travel or lost
work) or offset (e.g. productivity savings from averting paedi-
atric HIV infections) as a result of a screen-and-test strategy.
Lastly, we did not simulate alternative approaches to screen-
and-test. For example, on-site collection of infant heel-stick
samples in EPI clinics rather than referral to off-site EID
programmes (using either dried blood spots with shipment to
central laboratories or point-of-care NATs onsite) would likely
further improve the clinical benefits of screen-and-test pro-
grammes [5,79,80].
5 | CONCLUSIONS
We found that screening for infant HIV exposure at the first
infant immunization visit, followed by NAT for infants identi-
fied as exposed, would decrease MTCT among infants whose
mothers are undiagnosed or not virologically suppressed on
ART, would improve infant life expectancy among infants
with HIV, and may be cost-effective in South Africa and Zim-
babwe. In a low maternal HIV prevalence setting like Côte
d’Ivoire, screen-and-test is less likely to be cost-effective rela-
tive to existing health interventions. Results were robust
across a wide range of sensitivity analyses, indicating poten-
tial generalizability to a variety of high maternal HIV preva-
lence settings in sub-Saharan Africa. Linkage to infant NAT,
paediatric care and maternal care greatly influenced the pro-
jected infant life expectancy with both strategies, as well as
the cost-effectiveness of screen-and-test, and thus are critical
components to averting infant HIV-related mortality, reducing
MTCT and ensuring the cost-effectiveness of a screen-and-
test strategy.
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d’Ivoire. Antivir Ther (Lond). 2007;12:543–51.
54. Tapiwa M, Manenji A, Gboun M, Guthrie T, Nengoma A, Karume J, et al.
Zimbabwe national AIDS spending assessment: consolidated report 2011 and
2012. UNAIDS; 2012. Available from: https://www.unaids.org/en/dataanalysis/
knowyourresponse/nasacountryreports
55. Menzies NA, Berruti AA, Berzon R, Filler S, Ferris R, Ellerbrock TV, et al.
The cost of providing comprehensive HIV treatment in PEPFAR-supported pro-
grams. AIDS. 2011;25:1753–60.
56. Cleary S, Chitha W, Jikwana S, Okorafor O, Boulle A.South African health
review 2005. 2005 [cited 2018 Dec 21]. Available from: http://www.hst.org.za/
publications/South%20African%20Health%20Reviews/sahr05.pdf
57. Thomas LS.Costing of HIV/AIDS services at a tertiary level hospital in Gaut-
eng Province. Faculty of Health Sciences, University of Witwatersrand, South
Africa Published Online First: 2006 [cited 2018 Dec 12]. Available from: http://
wiredspace.wits.ac.za/bitstream/handle/10539/2008/Dr%20L%20S%20Thomas
%20MMed%20Report.pdf?sequence=2&isAllowed=y
58. Desmonde S, Avit D, Petit J, Amorissani Folquet M, Eboua FT, Amani Bosse
C, et al. Costs of care of HIV-infected children initiating lopinavir/ritonavir-based
antiretroviral therapy before the age of two in Côte d’Ivoire. PLoS One.
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